Log In
BCIQ
Print this Print this
 

DaxibotulinumtoxinA Injection (RT002)

  Manage Alerts
Collapse Summary General Information
Company Revance Therapeutics Inc.
DescriptionInjectable botulinum toxin type A that uses TransMTS technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$104.0M

$10.0M

$94.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/03/2009

$104.0M

$10.0M

$94.0M

Get a free BioCentury trial today